Alaunos Therapeutics, Inc.: 5%+ holders

Alaunos Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-07-01. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Stated intent

Intent stated in Item 4 Price Adrian

On December 4, 2025, Adrian Price sent a letter on behalf of the Reporting Persons to the Board of Directors of Alaunos Therapuetics, Inc. This letter requested the Board to appoint Gerald W.From Item 4 of the SCHEDULE 13D/A filed 2025-12-05

Holders

Purpose of Transaction (Item 4)

Postma Robert W

Mr. Postma is a director of the Issuer. Except in Mr. Postma's capacity as a director of the Issuer, the Reporting Persons do not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein. The Reporting Persons reserve the right to increase or decrease their position in the Issuer through, among other things, the purchase or sale of securities of the Issuer on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. The Reporting Persons reserve the right to change their intention with respect to any and all matters referred to in this Item 4. On June 24, 2025, WaterMill entered into a Subscription Agreement (the "Series A-2 Subscription Agreement") with the Issuer and the other purchasers party thereto, pursuant to which the Issuer agreed to issue and sell, in a private offering to the purchasers the Series A-2 Preferred Stock, at a price per share of $1,000 (the "Series A-2 Offering"). The Series A-2 Offering closed on June 24, 2025. The terms, rights, obligations and preferences of the Series A-2 Preferred Stock are set forth in the Certificate of Designation of Series A-2 Convertible Preferred Stock of the Issuer (the "Series A-2 Certificate of Designation"), filed with the Secretary of State of the State of Delaware on June 24, 2025. The holders of Series A-2 Preferred Stock …The first part of Item 4 of the SCHEDULE 13D filed 2025-07-01; the filing has the rest

Pmgc Capital LLC

Item 4 is hereby replaced in its entirety as follows: Between June 16, 2025 and August 22, 2025, PMGC LLC sold all of Common Stock of the Issuer on the open market at prices ranging between $1.92 to $4.53 (such sales, in the aggregate, the "Transactions"). As of August 25, 2025, PMGC LLC's settlement date of the August 22, 2025 sales of the Issuer's Common Stock, the Reporting Persons are no longer beneficial owners or no longer may be deemed to be beneficial owners (as the case may be), of any shares of Common Stock.Item 4 of the SCHEDULE 13D/A filed 2025-09-05

Price Adrian

On February 24, 2026, counsel for Adrian Price sent a letter on behalf of the Reporting Persons to counsel of Alaunos Therapeutics, Inc. (the "Company"), and requested that the Company's counsel provide the letter to the Company's Board of Directors ("Board"). In this letter, Mr. Price proposed a private placement whereby HexagonONE Ltd, Alimenta Holding Limited and Krakatau Holding Limited (the "Investors") would purchase $7,000,000 of securities of the Company subject to mutually agreeable definitive documentation and customary closing conditions. The securities purchased by the Investors would be equity or equity-linked securities, with the purchase price to be negotiated in good faith, taking into account market conditions, the Company's liquidity needs, and long-term shareholder alignment. The Investors proposed that the private placement close as soon as practicable following Board approval and completion of documentation and shareholder approval (if required by Nasdaq rules). The letter requested the Board meet with Mr. Price within five business days to begin term sheet negotiation and due diligence. The letter also reiterated the Reporting Persons' nomination of Gerald Bruce to the Board and requested that the Board appoint Mr. Bruce as a director. The letter stated that if the Board did not engage meaningfully with Mr. Price within this five business day period, then the Reporting Persons may seek to purchase additional shares of the Company in the market or …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-03-05; the filing has the rest

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes